Position in AGIO
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,869,082
-$3,573,488 QoQ
Shares Held
50,366
-68.7% QoQ
Ownership
0.084%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#87
of 238 holders
Holding Since
Jun 2023
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AGIO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026XTX Topco Ltd holds $414,894,447 across 381 Biotechnology names. AGIO ranks #66 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
30,522 | $19,031,687 | |
| 2 | ASND |
Ascendis Pharma A/S
|
43,289 | $11,546,042 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
116,611 | $8,685,187 | |
| 4 | MRNA |
Moderna, Inc.
|
123,281 | $8,633,368 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
30,496 | $7,348,621 | |
| 6 | KYMR |
Kymera Therapeutics, Inc.
|
61,501 | $7,052,319 | |
| 7 | CYTK |
Cytokinetics Inc
|
80,743 | $6,878,496 | |
| 8 | PTCT |
Ptc Therapeutics, Inc.
|
81,923 | $6,682,459 |
All Filings in AGIO
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,869,082 | 50,366 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $5,442,570 | 160,880 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $1,253,181 | 46,039 | Shares | Defined | 2026-02-17 | |
| 2025-03-31 | $404,369 | 13,801 | Shares | Defined | 2025-05-08 | |
| 2024-12-31 | $304,677 | 9,272 | Shares | Defined | 2025-02-13 | |
| 2024-09-30 | $370,057 | 8,329 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $229,958 | 5,333 | Shares | Defined | 2024-08-12 | |
| 2023-12-31 | $200,719 | 9,013 | Shares | Defined | 2024-02-13 | |
| 2023-09-30 | $252,549 | 10,204 | Shares | Defined | 2023-11-13 | |
| 2023-06-30 | $214,184 | 7,563 | Shares | Defined | 2023-08-14 | |
| No filing history on record for this holder in this stock. | ||||||